Group 1 - The company, Tibet Yiming Xiya Pharmaceutical Technology Co., Ltd., announced a significant change in control due to a share transfer agreement signed between the controlling shareholder Gao Fan and Beijing Fuhai, involving the transfer of 43,855,883 shares, which represents a substantial portion of the company's total shares [3][4]. - The company's stock experienced abnormal trading fluctuations, with a cumulative price deviation exceeding 20% over three consecutive trading days from July 23 to July 25, 2025 [2]. - The board of directors confirmed that there are no undisclosed significant matters or ongoing negotiations that would require disclosure under the Shenzhen Stock Exchange regulations, ensuring transparency in the company's operations [4][5]. Group 2 - The company is currently in the process of preparing its semi-annual report, and as of now, it has not reached the threshold that would necessitate a performance forecast disclosure according to the Shenzhen Stock Exchange rules [5]. - The company will continue to adhere strictly to legal and regulatory requirements regarding information disclosure and will ensure timely updates to stakeholders [4].

本次权益变动事项尚需取得深圳证券交易所的合规性确认意见并在中国证 券登记结算公司深圳分公司办理股份过户登记手续以及完成相关法律法规要求 可能涉及的其他批准，该事项能否最终实施完成及实施结果尚存在不确定性， 敬请投资者注意投资风险； 2、公司股票价格近期波动较大，存在短期市场情绪过热的情形，可能存在 非理性交易行为，交易风险较大。敬请广大投资者注意交易风险，理性决策， 审慎判断投资价值。 一、 股票交易异常波动的情况介绍 西藏易明西雅医药科技股份有限公司股票（证券代码：002826，证券简 称：易明医药）于2025年7月23日、2025年7月24日、2025年7月25日连续三个交 1 易日内日收盘价涨幅偏离值累计达到20％以上，根据深圳证券交易所的相关规 定，属于股票交易异常波动的情况。 证券代码：002826 证券简称：易明医药 公告编号：2025-051 西藏易明西雅医药科技股份有限公司 股票交易异常波动公告暨风险提示公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有 虚假记载、误导性陈述或重大遗漏。 重要风险提示： 1、西藏易明西雅医药科技股份有限公司（以下简称"公司"或"本公司"） 于 ...

Group 1 - The core point of the news is the transfer of control of Xizang Yiming Xiya Pharmaceutical Technology Co., Ltd. from Gao Fan to Beijing Fuhao Enterprise Management Partnership, with Beijing Fuhao acquiring 23.00% of the company's shares [1][2] - Following the completion of the equity transfer, Beijing Fuhao will hold 43,855,883 shares, making it the new controlling shareholder, while the actual controller will change to Yao Jinbo [1][2] - A supplementary agreement has been signed to address unfulfilled matters from the main agreement, including performance commitments and recovery of funds related to a previous investment [2]

证券代码：002826 证券简称：易明医药 公告编号：2025-050 西藏易明西雅医药科技股份有限公司 关于控制权拟发生变更的进展暨签署补充协议的公告 高帆保证向本公司提供的信息内容真实、准确、完整，没有虚假记载、 误导性陈述或重大遗漏。本公司及董事会全体成员保证公告内容与信息披露 义务人提供的信息一致。 一、本次权益变动的情况 2025 年 5 月 31 日，西藏易明西雅医药科技股份有限公司（以下简称"上市 公司"、"公司"）控股股东、实际控制人高帆与北京福好企业管理合伙企业（有 限合伙）（以下简称"北京福好"、"受让方"）签署了《股份转让协议》（以 下简称"主协议"），北京福好拟协议收购高帆持有的 43,855,883 股公司股份， 占上市公司股份总数的 23.00%。 本次权益变动完成后，北京福好将持有公司 43,855,883 股股份（占上市公司 股份总数的 23.00%），公司控股股东将由高帆变更为北京福好，实际控制人将 由高帆变更为姚劲波。 1、就公司控股子公司内蒙古博斯泰企业管理服务有限责任公司原股东王键 泽（简称"业绩承诺方"）业绩承诺事项，转让双方应配合并促使公司要求业绩 承诺方实际履行业 ...

Group 1: Stock Performance - Yiming Pharmaceutical achieved a 10.00% increase over two consecutive days, driven by developments in Tibet and medical technology [3] - Kantai Medical saw a first board listing with a 20.03% rise, attributed to medical device advancements [4] - Zhengchuan Co. also debuted on the first board with a 9.99% increase, linked to medicinal glass [3] - Yuheng Pharmaceutical and Tianmu Pharmaceutical both recorded first board listings with increases of 10.09% and 10.00% respectively, related to the pharmaceutical sector [3] Group 2: AI and Robotics - Zhi Zhen Technology and Zhongdian Xinlong both debuted on the first board with a 10.01% increase, associated with computing power and machine learning [6] - Hubei Broadcasting and Duolun Technology also saw first board listings with increases of 10.04% and 9.95%, driven by computing power and AI applications [7] - The M-Robots open-source project was announced, aiming to create a unified robot operating system [11] Group 3: Infrastructure and Energy - The announcement of a 1.2 trillion yuan investment in a super hydropower project has led to significant interest in related stocks [13][16] - Nanfang Road Machinery and Tuoshan Heavy Industry both achieved consecutive board listings with increases of 9.99% and 10.01%, linked to engineering machinery [15] Group 4: Tourism and Hospitality - The demand for various types of tourism, including educational and family trips, has surged, with national railways reporting 341 million passenger trips [18][19] - Sizhizang Tourism and Tianfu Cultural Tourism both recorded first board listings with increases of 9.99% and 10.04%, reflecting the growing tourism sector [20] Group 5: Market Trends - The stock market has shown a strong focus on sectors such as robotics, AI, and infrastructure, with multiple companies achieving significant stock price increases [22][23]

Investment Rating - The report maintains a "Recommended" investment rating for the healthcare sector [7]. Core Insights - The healthcare sector has shown a mixed performance, with the Shenyin Wanguo Pharmaceutical Bio Index rising by 1.60% from June 23 to June 27, 2025, underperforming the CSI 300 Index by 0.35 percentage points [2][12]. - Year-to-date, the pharmaceutical sector has increased by 6.24%, outperforming the CSI 300 Index by 6.57 percentage points, ranking 11th among 31 sectors [2][14]. - As of June 27, 2025, the valuation of the pharmaceutical sector stands at 27.54 times (TTM overall method, excluding negative values), with a premium of 140.94% compared to the CSI 300 [2][17]. Summary by Sections 1. Market Performance - The pharmaceutical sector's performance from June 23 to June 27, 2025, was a 1.60% increase, ranking 23rd among 31 sectors [12]. - The year-to-date performance shows a 6.24% increase, ranking 11th among 31 sectors [14]. 2. Important Events - The National Healthcare Security Administration released the "2025 Basic Medical Insurance Directory and Commercial Insurance Innovative Drug Directory Adjustment Application Guidelines," marking a significant step for commercial health insurance in the multi-level medical security system [4][21]. 3. Industry Perspective - The inclusion of the commercial insurance innovative drug directory indicates an enhanced role for commercial insurance in the multi-level medical security system, providing greater opportunities for the industry [5][22]. - The report expresses optimism for innovative drugs, overseas expansion, and the clearing of procurement in specific segments, suggesting a focus on companies involved in these areas [22].

Group 1 - Aike Cyber (688719.SH) shareholders Dachen Chuangtong and Dachen Chuanghong reduced their holdings by 2,298,151 shares, accounting for 1.99% of the total share capital, and did not complete the planned reduction [1] - Benchuan Intelligent (300964.SZ) controlling shareholder Dong Xiaojun reduced his holdings by 355,787 shares, accounting for 0.4582% of the total share capital, bringing his shareholding down to 21.64% [1] - Changlian Co., Ltd. (603648.SH) completed its reduction plan by selling 3,624,050 shares, which is 1% of the total share capital [1] Group 2 - Chuan Yi Technology (002866.SZ) controlling shareholder Zou Weimin and his concerted party reduced their holdings, with Zou's shareholding dropping to 48.53% [2] - Daoshi Technology (300409.SZ) controlling shareholder Rong Jihua plans to reduce his holdings by up to 15,416,611 shares, accounting for 1.97% of the total share capital [2] - Electric Alloy (300697.SZ) completed its reduction plan by selling 2,741,390 shares, which is 0.63% of the total share capital [2] Group 3 - Fujirei (688272.SH) shareholders Suzhou Kongkong, Suzhou Zhaorong, and Shanghai Zhaoren reduced their holdings by 1,215,618 shares, 1,463,490 shares, and 44,944 shares, accounting for 1.60%, 1.93%, and 0.06% of the total share capital respectively [3] - Gaoweida (300465.SZ) controlling shareholder Yingtan Yinggao Investment Consulting Co., Ltd. reduced its holdings by 4,261,700 shares, accounting for 0.96% of the total share capital, bringing its shareholding down to 22.00% [3] - Haizheng Materials (688203.SH) shareholder Sinopec Capital plans to reduce its holdings by up to 3,525,600 shares, accounting for 1.74% of the total share capital [3] Group 4 - Hangyu Micro (300053.SZ) shareholder Yan Jun reduced his holdings by 3,930,000 shares, accounting for 0.56% of the total share capital [4] - He Shi Eye Hospital (301103.SZ) shareholder Advanced Manufacturing Industry Investment Fund plans to reduce its holdings by up to 3,106,074 shares, accounting for 2% of the total share capital [4] - He Yuan Gas (002971.SZ) shareholder Baishide Chuangye completed its reduction plan by selling 854,064 shares, which is 0.415% of the total share capital [4] Group 5 - Huaren Health (301408.SZ) shareholder Saifu Investment reduced its holdings by 2,107,696 shares, accounting for 0.53% of the total share capital [5] - Jiangsu Boyun (301003.SZ) shareholder Gong Wei reduced his holdings by 1,558,900 shares, accounting for 1.57% of the total share capital [5] - Jeya Co., Ltd. (301108.SZ) shareholders Mingyuan Fund and its concerted party did not reduce their holdings, and the reduction plan period expired [5] Group 6 - Longxin General (603766.SH) directors plan to reduce their holdings by up to 350,000 shares and 100,000 shares, accounting for 0.0170% and 0.0049% of the total share capital respectively [6] - Ruchuang Micro-Nano (688002.SH) shareholder Li Weicheng plans to reduce his holdings by up to 8,000,000 shares, accounting for 1.75% of the total share capital [6] - Shilan Micro (600460.SH) shareholder Luo Huabing plans to reduce his holdings by up to 500,000 shares, accounting for 0.03005% of the total share capital [6] Group 7 - Tongfu Microelectronics (002156.SZ) shareholder National Integrated Circuit Industry Investment Fund reduced its holdings by 15,175,969 shares, accounting for 1% of the total share capital [7] - Wangzi New Materials (002735.SZ) controlling shareholder Wang Jinjun reduced his holdings by 9,717,874 shares, accounting for 2.54% of the total share capital [7] - Xingye Co., Ltd. (603928.SH) shareholder Shen Genzhen reduced his holdings by 2,620,000 shares, accounting for 1.00% of the total share capital [7] Group 8 - Yikang Co., Ltd. (301085.SZ) controlling shareholder concerted party reduced its holdings by 633,700 shares, accounting for 0.73% of the total share capital [8] Group 9 - Yiming Pharmaceutical (002826.SZ) major shareholder Zhou Zhan reduced his holdings by 3,586,777 shares, accounting for 1.88% of the total share capital [9] - Yiming Pharmaceutical (002826.SZ) director Xi Ke reduced his holdings by 283,862 shares, accounting for 0.15% of the total share capital [9] - Youyan Powder Materials (688456.SH) concerted party reduced its holdings by 1,030,000 shares, accounting for 0.99% of the total share capital [9] Group 10 - Zhongma Transmission (603767.SH) directors plan to reduce their holdings through block trading and centralized bidding [10] - Zhongqi Co., Ltd. (301215.SZ) shareholder Jiangsu Yueda Group did not reduce its holdings, and the reduction plan period expired [10]

Core Viewpoint - The company disclosed a share reduction plan by a major shareholder, Mr. Lic, who intends to reduce his holdings by up to 300,000 shares within a specified timeframe [1] Group 1: Shareholder Reduction Details - Mr. Lic's share reduction occurred from April 1 to April 12, 2025, with an average reduction price of 11.42 yuan per share, totaling 283,862 shares, which represents 0.15% of the company's total share capital [1] - Before the reduction, Mr. Lic held 1,215,447 shares (0.64% of total share capital), and after the reduction, he holds 931,585 shares (0.49% of total share capital) [1] - The shares reduced were sourced from Mr. Lic's holdings prior to the company's initial public offering and from equity incentive shares [1] Group 2: Compliance and Governance - The reduction plan complies with relevant regulations, including self-regulatory guidelines and stock exchange rules [1] - Mr. Lic has no outstanding commitments related to share changes that have not been disclosed and fulfilled [1] - The share reduction will not lead to a change in the company's control or affect its governance structure and ongoing operations [1]

证券代码：002826 证券简称：易明医药 公告编号：2025-049 西藏易明西雅医药科技股份有限公司 关于董事减持股份计划期限届满暨实施结果的公告 董事许可先生保证向本公司提供的信息内容真实、准确、完整，没有虚假记 载、误导性陈述或重大遗漏。 近日，公司收到许可先生出具的《关于股份减持计划期限届满暨实施结果的 告知函》。截至本公告披露日，上述减持计划期限已届满，根据相关规定，现将 具体情况公告如下： 一、 股东减持情况 1、股东减持股份的情况 | 股东 | 减持 | | 减持时间 | | | 减持均价 | 减持数量 | 占总股本比例（%） | 占剔除公司回购专用账户股 | | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | | 名称 | 方式 | | | | | （元/股） | （股） | | 份后总股本比例（%） | | 许可 | 集中 竞价 | 2025 2025 | 年 4 1 年 5 | 月 月 | 日至 12 日 | 11.42 | 283,862 | 0.15 | 0.15 | | 合计 | -- | | -- | | | ...

证券代码：002826 证券简称：易明医药 公告编号：2025-048 西藏易明西雅医药科技股份有限公司 关于持股 5%以上股东减持触及 1%暨减持计划期限届满的 公告 董事、持股 5%以上股东周战先生保证向本公司提供的信息内容真实、准 确、完整，没有虚假记载、误导性陈述或重大遗漏。 本公司及董事会全体成员保证公告内容与信息披露义务人提供的信息一 致。 西藏易明西雅医药科技股份有限公司（以下简称"公司"）于 2025年3月10 日披露了《关于公司董事、持有5%以上股东减持股份的预披露公告》（公告编 号：2025-011）。持有公司股份14,361,702股（占公司总股本比例的7.5319%）的 董事、持股5%以上股东周战先生，计划自公告披露之日起15个交易日后的3个月 内，以集中竞价方式或大宗交易方式减持公司股份不超过3,590,000股（不超过公 司总股本比例的1.8828%）。 公司于2025年6月20日披露了《关于公司持股5%以上股东减持触及1%的公 告》（公告编号：2025-046），周战先生于2025年6月11日至2025年6月18日以集 中竞价方式累计减持公司股份1,906,777股，占公司总股本 ...